Abstract: Delayed release compositions comprising an active compound and glassy amylose. A variety of different types of active compound may be employed in the compositions. The compositions are particularly adapted for achieving the selective release of medicaments into the colon.

Abstract: Neurological therapy devices are disclosed for the local and controlled delivery of a neurotransmitter to the brain of a subject suffering from neurotransmitter deficiency or dysfunction. In one embodiment the device includes a biocompatible, implantable, and retrievable polymeric insert including a source of neurotransmitter embedded therein. In another embodiment, the device includes a retrievable source of neurotransmitter including at least one neurotransmitter-secreting cell encapsulated within a semipermeable membrane allowing the diffusion therethrough of the neurotransmitter, and further includes a source of growth factor in close proximity to the neurotransmitter-secreting cells.

Abstract: A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase I and show anti-leukemic and anti-tumor activity.

Abstract: A system for stabilizing fibroblast-derived growth factors, maintaining their bioactivity over a prolonged period of time and controllably releasing them for use is disclosed. The system uses growth factors bound to biocompatible substrates via heparin or heparin derived compounds to maintain the bioactivity of the growth factors. A growth factor bound to a heparin coated substrate can be used independently as a controlled release device, or can be incorporated into a reservoir or matrix type controlled release devices to further enhance the controlled release properties. The stabilized growth factors can be implanted into a patient, thereby providing a means for producing an in vivo controlled release of a growth factor to the patient.

Abstract: Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.

Abstract: Hypoxic cells are rendered more sensitive to irradiation by subjecting the cells to treatment with a Cu(II) coordination compound.

Abstract: Heterocyclic compounds of the general formula: ##STR1## wherein R.sup.11 is a hydroxyl group or a lower alkoxy group, R.sup.12 is a lower alkoxy group, R.sup.13 is a saturated or unsaturated hydrocarbon group, X is an oxygen atom or a sulfur atom, and Y is an oxygen atom or --NH-- which may have a lower alkyl substituent, or salts thereof are novel and effective in controlling carcinoma.

Abstract: Water-insoluble drugs are rendered injectable by formulation as aqueous suspensions of phospholipid-coated microcrystals. The crystalline drug is reduced to 50 nm to 10 .mu.m dimensions by sonication or other processes inducing high shear in the presence of phospholipid or other membrane-forming amphipathic lipid. The membrane-forming lipid stabilizes the microcrystal by both hydrophobic and hydrophilic interactions, coating and enveloping it and thus protecting it from coalescence, and rendering the drug substance in solid form less irritating to tissue. Additional protection against coalescence is obtained by a secondary coating by additional membrane-forming lipid in vesicular form associated with and surrounding but not enveloping the lipid-encapsulated drug particles. Tissue-compatible formulations containing drug in concentrations up to 40% (w/v) are described.

Abstract: An embalming fluid. A chemical composition comprising chemicals that are, generally, non-hazardous to humans in the concentrations used. Also, specimens preserved in the composition look and feel more life-like than specimens preserved in formaldehyde based compositions.

Abstract: Water-insoluble drugs are rendered injectable by formulation as aqueous suspensions of phospholipid-coated microcrystals. The crystalline drug is reduced to 50 nm to 10 um dimensions by sonication or other processes inducing high shear in the presence of phospholipid or other membrane-forming amphipathic lipid. The membrane-forming lipid stabilizes the microcrystal by both hydrophobic and hydrophilic interactions, coating and enveloping it and thus protecting it from coalescence, and rendering the drug substance in solid form less irritating to tissue. Additional protection against coalescence is obtained by a secondary coating by additional membrane-forming lipid in vesicular form associated with and surrounding but not enveloping the lipid-encapsulated drug particles. Tissue-compatible formulations containing drug in concentrations up to 40% (w/v) are described.

Abstract: A sterile lipid emulsion composition made from fish oil enriched egg phosphatides; a natural oil, an osmotic agent such as glycerin and purified water, optionally adjusted to a pH of between 8.5 and 10.5 with sodium hydroxide. This composition can be administered parenterally to a host mammal.

Abstract: A method for treating cachexia is provided, comprising the step of administering to a patient an amount of macrophage colony-stimulating factor (M-CSF) effective for said treatment.

Abstract: Pathological collagen cross-linking, caused in diabetes patients on account of the higher glucose concentrations, may be inhibited by means of arginine, spermidine, creatine, or agmatine, or a pharmaceutically acceptable salt thereof, in the amount of 1 to 4 g/day.

Abstract: An analgesic composition useful in providing temporary relief from the symptoms of arthritis is disclosedng having the following components in approximately the stated weight-percentages ranges:______________________________________ Water (Deionized) 86.00-95.35% by weight; Carbopol 934 0.5-2.00% by weight; Methylparaben 0.1-0.40% by weight; Propylparaben 0.05-0.20% by weight; Hampene 100 0.05-0.20% by weight; Aloe Vera Gel 0.05-2.00% by weight; Benzyl Alcohol 0.30-1.20% by weight; Camphor (U.S.P.) 0.50-2.00% by weight; Menthol (U.S.P.) 1.00-4.00% by weight; Thymol 0.10-0.60% by weight; Eugenol 0.10-0.60% by weight; Witch Hazel 0.05-1.50% by weight; Isopropyl Alcohol 0.05-1.50% by weight; Eucalyptus Oil 0.50-2.00% by weight; Triethanolamine 0.50-2.00% by weight; and, Quaternium-15 0.10-0.40% by weight.

Abstract: A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier, in which the fluoride source provides a molar ratio of fluoride ion to hydantoin in the composition of from about 0.1:1 to about 100:1. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

Abstract: A composition for use an an insulin mimic comprising substances containing:a) vanadate; andb) peroxide.

Abstract: Disclosed is a composition for regulating hair growth comprising a safe and effective amount of a polypeptide having the structure of those derived from dermal papilla cells with characteristics of apparent isoelectric pH/molecular weight selected from the group consisting of pI 5.1/45kD, pI 5.2/43kD, pI 5.2/40kD, pI 7.3/25kD, pI 7.4/25kD, or active fragment of these polypeptides, and mixtures thereof; and a pharmaceutically-acceptable carrier.

Abstract: A stable rapidly dissolving lyophilized composition of cyclophosphamide and alanine is provided.

Abstract: The present invention relates to a serum for passive immunization of fish against furunculosis caused by Aeromonas salmonicida, which comprises antibodies against A. salmonicida isolated from fish naturally infected with furunculosis in an intraperitoneal injectable carrier. There is also provided a method for preparing a serum for passive immunization of fish against furunculosis caused by Aeromonas salmonicida, comprising the steps of: a) administering to a mammal selected from the group consisting of bovine, ovine, caprine and equine a sufficient amount of A. salmonicida to produce antibodies; b) collecting from the mammal the serum containing the antibodies against A.

Abstract: A process for the preparation of a hard candy containing an enzyme is disclosed, which comprises steps of preparing an unusual hard candy containing no enzyme, crushing the same into particles, mixing the enzyme with the candy particles, press treating the mixture to form a shaped mass, putting the mass into a pressure vessel, heating the vessel under pressurized inert gas to cause a partial melt of the mass, cooling the vessel to make the mass into the hard candy product, and releasing the pressure in the vessel.